CYTOKINETICS BEGINS CLINICAL TRIAL FOR SB-743921

A A

Cytokinetics has announced the initiation of a Phase I/II clinical trial of its second Kinesin Spindle Protein (KSP) inhibitor, SB-743921, in patients with non-Hodgkin's lymphoma.

The trial is an open-label, non-randomized study to investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of SB-743921, administered as a one-hour infusion on days 1 and 15 of a 28 day schedule. The objective of the Phase I portion of the clinical trial is to identify the maximum tolerated dose (MTD) of SB-743921 on this schedule, in patients with either Hodgkin's or non-Hodgkin's lymphoma, first without prophylactic administration of granulocyte colony stimulating factor (GCSF). If the dose-limiting toxicity determining this first MTD is neutropenia, a second MTD will be determined with SB-743921 given with prophylactic administration of GCSF.